| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥73.1B | ¥58.1B | +25.9% |
| Operating Income | ¥1.9B | ¥-3.4B | - |
| Ordinary Income | ¥2.2B | ¥-3.0B | - |
| Net Income | ¥2.1B | ¥-0.2B | +210.4% |
| ROE | 1.8% | -0.2% | - |
FY2026 Q3 results show revenue of 7.31B yen (YoY +25.9%), operating income of 0.19B yen (return to profitability from prior year loss of -0.34B yen), ordinary income of 0.22B yen (versus prior year loss of -0.30B yen), and net income of 0.21B yen (YoY +210.4% from prior year loss of -0.02B yen). The company achieved a significant turnaround at the operating level, recovering from operational losses in the prior year period. Revenue growth was robust at over 25%, driven primarily by expanded sales across business segments. However, profitability remains modest with net margin of 2.9% and operating margin of 2.6%, indicating that selling, general and administrative expenses continue to constrain earnings conversion. A notable contributor to bottom-line improvement was a one-time gain of 1.71B yen from sales of investment securities, which substantially boosted net income. The company maintained its full-year forecast of 10.0B yen in revenue and 0.20B yen in operating income, implying that Q4 performance will be critical to achieving these targets.
[Profitability] Return on equity of 1.8% reflects limited capital efficiency, driven by net profit margin of 2.9%, asset turnover of 0.46, and financial leverage of 1.31x. Operating margin stands at 2.6%, representing a substantial improvement from the prior year operating loss but remaining at a low absolute level due to high selling, general and administrative expenses of 3.32B yen relative to gross profit of 3.51B yen. The gross profit margin of 48.0% indicates healthy manufacturing and product margins, but operational efficiency in managing overhead costs requires material improvement. EBIT margin of 2.6% with interest burden coefficient of 1.19 and tax burden coefficient of 0.97 results in the modest ROE outcome. [Cash Quality] Cash and deposits of 1.67B yen decreased 43.5% year-over-year from 2.96B yen, primarily due to expansion in operating working capital through increased accounts receivable and inventory. Short-term debt coverage ratio stands at 1.67x (cash and deposits of 1.67B yen versus short-term borrowings of 0.10B yen), indicating adequate immediate liquidity. [Investment Efficiency] Asset turnover of 0.46 reflects underutilization of the asset base, with total assets of 15.84B yen supporting annualized revenue run-rate. Days sales outstanding extended to 177 days and days inventory outstanding to 342 days, resulting in a cash conversion cycle of 444 days, which represents significant capital tied up in working capital. Return on invested capital showed decline according to quality alerts, indicating deteriorating efficiency of capital deployment. [Financial Health] Equity ratio of 76.3% (equity of 12.09B yen versus total assets of 15.84B yen) demonstrates strong capitalization. Current ratio of 400.3% and quick ratio of 303.0% reflect robust short-term liquidity position. Total interest-bearing debt of 0.10B yen results in debt-to-equity ratio of 0.01 and debt-to-capital ratio of 0.8%, indicating minimal leverage and conservative capital structure.
Cash and deposits decreased 1.28B yen year-over-year, declining 43.5% from 2.96B yen to 1.67B yen, representing a material drain on liquidity despite the return to profitability. This cash consumption was driven primarily by significant expansion in operating working capital, with accounts receivable increasing 0.98B yen (up 38.0% to 3.55B yen) substantially outpacing the 25.9% revenue growth rate, and inventory buildup contributing to the extended cash conversion cycle of 444 days. The receivables increase suggests either extended payment terms granted to customers or collection delays, as reflected in the 177-day collection period. Investment securities increased 0.54B yen (up 29.4% to 2.39B yen), indicating capital allocation toward financial assets, though partial liquidation of 1.71B yen in securities sales provided a financing source during the period. The company maintained minimal reliance on external financing, with interest-bearing debt remaining stable at 0.10B yen. Working capital efficiency deteriorated substantially, with the operating working capital turnover extending to unfavorable levels. The current ratio of 400.3% and liquid assets of 5.88B yen against current liabilities of 1.47B yen provide adequate buffer for near-term obligations, though the trajectory of cash decline warrants attention. The mismatch between profit growth and cash generation, combined with extended working capital cycles, indicates that earnings quality from a cash realization perspective requires improvement through enhanced collections management and inventory optimization.
Ordinary income of 0.22B yen versus operating income of 0.19B yen indicates minimal net contribution of 0.03B yen from non-operating activities, demonstrating that core operating performance drives overall profitability with limited distortion from financial income or expenses. Non-operating income primarily comprised interest and dividend income of 0.09B yen and foreign exchange gains, partially offset by non-operating expenses including interest expenses of 0.00B yen, resulting in the modest net non-operating contribution of approximately 0.4% relative to revenue. The more significant earnings quality consideration arises from extraordinary items, where gains on sales of investment securities of 1.71B yen contributed substantially to pretax income of 0.22B yen, meaning that special items exceeded ordinary income. This one-time gain represents 76% of the final net income of 0.21B yen after taxes, indicating that recurring operational profitability is materially lower than reported bottom-line results. While the return to operating profitability from prior year losses marks an important milestone, the underlying EBIT margin of 2.6% demonstrates limited operational earnings power. The quality of earnings from a cash perspective shows concerns, as the substantial increases in accounts receivable (up 38.0%) and inventory levels resulting in 342-day inventory turnover significantly outpaced profit growth, suggesting that accruals constitute a large portion of reported earnings and cash conversion lags substantially behind accounting profits. The extended cash conversion cycle of 444 days and declining cash position despite profitability indicate that earnings are not yet translating efficiently into operating cash generation, warranting monitoring of working capital normalization in subsequent periods.
Working capital management risk: Accounts receivable increased 38.0% and inventory turnover extended to 342 days, resulting in a cash conversion cycle of 444 days. The 12.8B yen cash decline (down 43.5%) despite return to profitability indicates material capital tied up in working capital, creating liquidity pressure and potential collection or obsolescence risks if sales momentum slows or customers delay payments.
Earnings sustainability risk: Operating margin remains at low level of 2.6% with EBIT of only 0.19B yen on revenue of 7.31B yen, while net income of 0.21B yen was materially boosted by one-time investment securities sale gain of 1.71B yen. Recurring operational profitability excluding special items is insufficient to support current dividend commitment of 3.00 yen per share without continued asset monetization or material improvement in operating efficiency.
Operational efficiency risk: Selling, general and administrative expenses of 3.32B yen consumed 45.4% of revenue and 94.6% of gross profit, indicating cost structure remains elevated relative to sales base. Without successful expense ratio reduction through operating leverage as revenue scales, the company faces ongoing pressure to achieve sustainable profitability targets, particularly the full-year operating income forecast of 0.20B yen which requires substantial Q4 margin improvement.
[Industry Position] (Reference - Proprietary Analysis)
Wakamoto Pharmaceutical demonstrates contrarian performance relative to the pharmaceutical industry peer group for 2025-Q3. Profitability: Operating margin of 2.6% substantially exceeds the industry median of -218.2% (IQR: -628.8% to -14.9%, n=13 companies), placing the company in a favorable position as it achieved positive operating profitability while the majority of peers remain in loss-making territory. Net profit margin of 2.9% similarly outperforms the industry median of -216.8% (IQR: -725.8% to -24.6%). Growth: Revenue growth of 25.9% significantly outpaces the industry median decline of -12.5% (IQR: -22.1% to -2.5%), indicating strong top-line momentum against an industry experiencing contraction. Returns: ROE of 1.8% compares favorably to industry median ROE of -35.8% (IQR: -91.4% to -6.1%), though the absolute level of return remains modest. ROA of 1.4% versus industry median of -23.9% demonstrates relatively better asset utilization. Efficiency: Asset turnover of 0.46 substantially exceeds the industry median of 0.17 (IQR: 0.05-0.24), indicating more effective revenue generation per unit of assets deployed. However, receivables turnover of 177 days compares unfavorably to industry median of 152 days (IQR: 87-301 days), and inventory turnover of 342 days materially exceeds the industry median of 282 days (IQR: 146-302 days), suggesting working capital management lags peer practices. Operating working capital turnover of 444 days significantly exceeds the industry median of 149 days (IQR: 65-201 days), representing an area requiring improvement. Financial Health: Equity ratio of 76.3% aligns closely with industry median of 67.8% (IQR: 62.1%-79.1%), indicating comparable capital strength. Current ratio of 400.3% substantially exceeds the industry median of 662% (IQR: 466%-918%), though the company maintains adequate liquidity. Financial leverage of 1.31x falls below the industry median of 1.47x (IQR: 1.24-1.58), reflecting more conservative capital structure. Overall, the company demonstrates superior profitability and growth versus a pharmaceutical peer group predominantly operating at losses, though operational working capital efficiency represents a relative weakness requiring management focus.
(Industry: Pharmaceutical, Comparison: 2025-Q3, Source: Proprietary analysis)
Revenue momentum of 25.9% growth against industry contraction of -12.5% median decline, combined with return to operating profitability from prior year losses, positions the company favorably within a challenging pharmaceutical sector environment. The achievement of positive operating margin of 2.6% while industry median remains deeply negative at -218.2% indicates relative competitive strength or successful portfolio repositioning. However, the quality and sustainability of this performance improvement warrants scrutiny given the low absolute profitability level and material working capital deterioration.
Earnings quality concerns arise from the composition of profitability, as net income of 0.21B yen was substantially enhanced by one-time investment securities sale gains of 1.71B yen, meaning recurring operational earnings power remains limited. The cash generation profile shows disconnect from reported profits, with cash declining 1.28B yen (down 43.5%) despite return to profitability, driven by accounts receivable increasing 38.0% against 25.9% revenue growth and inventory turnover extending to 342 days. The resulting cash conversion cycle of 444 days materially exceeds the pharmaceutical industry median of 149 days, indicating capital inefficiency that constrains financial flexibility and sustainability of current dividend policy with 48.6% payout ratio dependent on non-recurring gains.
Full-year forecast achievement requires substantial Q4 improvement, as nine-month revenue of 7.31B yen implies 10.0B yen full-year target necessitates 2.69B yen in Q4 (up from implied quarterly average of 2.44B yen in Q1-Q3), and operating income of 0.19B yen through Q3 against 0.20B yen full-year target leaves minimal margin for error. Management execution on working capital normalization through enhanced collection processes and inventory optimization, along with sustained operating expense discipline to expand EBIT margin from current 2.6% level, represent critical value drivers for validating the operational turnaround and transition from asset monetization to sustainable cash-generative profitability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.